KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Net Margin: 2011-2024

Historic Net Margin for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -1.46%.

  • Esperion Therapeutics' Net Margin rose 2359.00% to -36.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -35.47%, marking a year-over-year decrease of 2145.00%. This contributed to the annual value of -1.46% for FY2024, which is 18296.00% up from last year.
  • Esperion Therapeutics' Net Margin amounted to -1.46% in FY2024, which was up 99.21% from -184.42% recorded in FY2023.
  • Esperion Therapeutics' 5-year Net Margin high stood at -1.46% for FY2024, and its period low was -348.11% during FY2021.
  • In the last 3 years, Esperion Therapeutics' Net Margin had a median value of -184.42% in 2023 and averaged -166.32%.
  • As far as peak fluctuations go, Esperion Therapeutics' Net Margin crashed by 28,480bps in 2021, and later surged by 18,296bps in 2024.
  • Esperion Therapeutics' Net Margin (Yearly) stood at -63.31% in 2020, then crashed by 28,480bps to -348.11% in 2021, then surged by 3,501bps to -313.10% in 2022, then skyrocketed by 12,868bps to -184.42% in 2023, then spiked by 18,296bps to -1.46% in 2024.